Pharmacy & Compounding Fraud Defense
Former DOJ Fraud Section Prosecutors. Nationwide Defense for Pharmacists, Pharmacy Owners, Compounding and 503B Operators, Sales Representatives, Prescribers, and Telehealth Pharmacy Executives in Federal Fraud, TRICARE, FDCA, and DEA Proceedings.
At DOJ, Scott Armstrong served as lead counsel in a $120 million compounding pharmacy fraud case involving pharmacy executives, pharmacists, prescribing physicians, and marketers.
Based in Washington, D.C., Armstrong & Bradylyons PLLC defends pharmacists, pharmacy owners, compounding and outsourcing facility operators, sales representatives, prescribers, and pharmacy and telehealth executives in federal pharmacy, compounding, and TRICARE fraud matters nationwide. The work spans criminal prosecutions, False Claims Act litigation, FDA regulatory proceedings, and DEA registration actions.
The firm’s healthcare fraud defense practice is built on nearly a decade of combined service at the Healthcare Fraud Unit of DOJ’s Fraud Section. Scott Armstrong served as lead counsel in a $120 million compounding pharmacy fraud case that presented the full range of issues these prosecutions raise: kickbacks between the pharmacy and prescribers, formulations built around reimbursement rather than therapy, fraudulent billing to federal programs, and financial tracing through multiple entities. He also directed DOJ’s Appalachian Regional Prescription Opioid Strike Force, which gives the firm depth in controlled substances dispensing cases.
Two structural changes reshaped this area. DOJ created the Health and Safety Unit on November 30, 2025 with 23 prosecutors to handle criminal Food, Drug, and Cosmetic Act cases, and on April 7, 2026 created the National Fraud Enforcement Division and moved the Healthcare Fraud Unit under it. A compounding pharmacy now faces fraud prosecutors and FDCA prosecutors in the same component.
Enforcement reaches across agencies. DOJ, HHS-OIG, the FBI, the DEA, the Defense Criminal Investigative Service, IRS-CI, and the FDA all work pharmacy cases, often in the same investigation.
The government tries these cases. DOJ’s Healthcare Fraud Unit completed nine jury trials through early June 2026, convicting in all of them, after 17 trials in 2025. The largest recent compounding prosecution ran six weeks before a jury.
The firm’s attorneys know how these cases are built because they built them. Scott Armstrong served nearly a decade at DOJ’s Fraud Section as lead trial counsel in 16 federal jury trials. In the $120 million compounding matter he analyzed the formulation evidence, developed the financial tracing, and managed the cooperating witness strategy. Drew Bradylyons served as Chief of EDVA’s Financial Crimes and Public Corruption Unit and supervised the Healthcare Fraud Unit’s Florida Strike Force at DOJ, overseeing parallel criminal, civil, and administrative proceedings.
Pharmacy cases are built from claims data, dispensing logs, wholesaler purchase records, formulation files, commission statements, and cooperating employees. The firm develops that record early: retaining compounding and pharmacology experts, reconciling purchase and dispensing data before the government’s summary exhibits are finalized, and testing former employees and sales representatives before they are locked into testimony.
Compounding and TRICARE
Compounding became a federal priority when TRICARE compound spending rose from roughly $24 million in 2010 to more than $500 million in 2014, with compounds under one percent of prescriptions but about 20 percent of TRICARE pharmacy costs. Those cases are still being tried. In March 2025, two executives of a Louisiana compounding pharmacy were convicted after a six-week trial of defrauding TRICARE and New Jersey benefit programs of approximately $100 million by designing formulations around reimbursement and submitting test claims using real patients’ identities. Fifty people have been convicted or pleaded guilty in that conspiracy.
Sentencings continued through 2026. In April 2026, the former president of a New Jersey mail-order pharmacy was sentenced to 24 months in a $33 million compounded cream and vitamin scheme, with $33 million in restitution and $27 million in forfeiture. Principals in the largest compounding cases have received 18 years.
Retail and Chain Pharmacy Dispensing
Dispensing enforcement moves on both civil and criminal tracks. A jury returned a $948.8 million judgment against the nation’s largest long-term care pharmacy and its parent for dispensing without valid prescriptions. Walgreens agreed to pay up to $350 million over invalid controlled substance prescriptions billed to federal programs, and Walmart resolved the government’s Controlled Substances Act dispensing case for $50 million in August 2026. Individual pharmacists face prison: the pharmacist who filled for a Houston-area pill mill received 42 months in 2026. The theory is constant. The pharmacy’s own dispensing data showed the red flags, and it filled anyway.
False Claims Act Exposure
False Claims Act recoveries reached a record in fiscal year 2025, exceeding $6.8 billion, with healthcare accounting for more than $5.7 billion and a record 1,297 qui tam filings. The 2026 docket continues the pattern. In January 2026, four New Jersey pharmacies paid $4.325 million over claims for drugs never dispensed, proved by comparing wholesaler purchase records against billed prescriptions. In March 2026, DOJ obtained a $31 million judgment against a pharmacy salesman for referral kickbacks, roughly $16.3 million in trebled damages and $14.7 million in penalties.
Compounded GLP-1 Products and the FDCA
Compounded semaglutide and tirzepatide are the most active compounding enforcement area. Once FDA declared the shortages resolved, the exception permitting 503A pharmacies and 503B facilities to compound copies closed. Letters followed in waves: more than 40 to telehealth-based compounding pharmacies in late 2025, 30 in March 2026, a round in April 2026 on research-use-only labeling and unapproved agonists, and 25 more in June 2026. FDA has said retatrutide and cagrilintide may not be compounded, issued an import alert for GLP-1 active ingredients, and reported over 1,700 adverse events tied to compounded semaglutide and tirzepatide as of May 21, 2026.
The regulatory track converts to a criminal one. In February 2026, FDA announced it would restrict GLP-1 active ingredients used in mass-marketed compounded products and named a major telehealth company, and HHS referred that company to DOJ over potential FDCA and Title 18 violations. The firm’s peptide and GLP-1 practice covers this area in detail.
DEA Registration Actions
DEA reported a record 928 administrative actions against registrants in the year ending with the June 2026 National Health Care Fraud Takedown: 205 Orders to Show Cause, 53 Immediate Suspension Orders, and 642 surrenders for cause. An Immediate Suspension Order stops all controlled substance dispensing the day it is served, before any hearing.
A pharmacy matter rarely stays on one track. An FDA inspection, a DEA registration action, a payer audit, a sealed qui tam complaint, and a grand jury investigation can run at once, and each generates statements the others can use.
Challenging the Claim That Compounds Were Built for Reimbursement
The government’s core theory is that formulations were engineered to maximize payment rather than treat patients, proved with high-cost ingredients, products that duplicate commercially available drugs, and internal testing of ingredient combinations against reimbursement schedules. The firm retains pharmacology and compounding experts to establish the therapeutic rationale for each formulation, the prescriber’s role in selecting it, and compliance with 21 U.S.C. § 353a, § 353b, and state board requirements.
Marketing and Sales Compensation Under the AKS and EKRA
Prosecutors treat percentage-based and per-prescription compensation as direct evidence of a kickback under the Anti-Kickback Statute and, for pharmacies, under EKRA, which reaches all payors with a narrower employee compensation exception. Copay waivers and purported assistance programs draw the same scrutiny. The firm analyzes each arrangement against the applicable safe harbors and separates documented marketing services from payment for referrals.
Reconciling Purchase Records, Dispensing Logs, and Claims
Billing cases are proved with arithmetic. Investigators compare wholesaler purchase records against billed prescriptions to show the pharmacy could not have dispensed what it billed, and examine short-fills, brand-for-generic substitution, and prior authorization submissions. The firm retains billing experts to reconcile those data sets, account for inventory transfers, returns, partial fills, and contract pharmacy arrangements, and show where the inference breaks down.
Inspections, Form 483s, Warning Letters, and Criminal Referrals
An FDA inspection can produce a Form 483, a warning letter, a seizure or injunction action, or a referral to DOJ’s Health and Safety Unit. Prior notice converts an FDCA misdemeanor into a felony: a violation committed with intent to defraud or mislead is prosecuted under 21 U.S.C. § 333(a)(2). The firm drafts inspection and warning letter responses with that exposure in mind, because each becomes a potential exhibit.
Corresponding Responsibility and Suspension Proceedings
A registration can be suspended before any charge. An Immediate Suspension Order under 21 U.S.C. § 824(d) halts dispensing on service; an Order to Show Cause starts a 30-day clock and preserves the right to a corrective action plan. The theory is failure of corresponding responsibility under 21 C.F.R. § 1306.04, answered with the verification performed: prescriber contacts, monitoring program checks, and refusals to fill.
Good Faith and the Management of Parallel Proceedings
Healthcare fraud and kickback convictions require knowing and willful conduct. The firm develops evidence of compliance programs, legal review of marketing agreements, and reliance on counsel, and attacks cooperating former employees on their agreements and incentives. It also sequences the response across forums, because an audit reply, an FDA submission, or a DEA filing made without regard to the criminal exposure can supply the government’s best evidence.
These investigations reach the whole chain: the pharmacist at the bench, the owner who set the business model, the sales force that generated prescriptions, the prescriber who signed, and the executives above them.
Pharmacists
Pharmacists face criminal exposure when the government alleges they dispensed controlled substances despite red flags, compounded formulations built around reimbursement, billed for prescriptions not dispensed, or failed their corresponding responsibility under 21 C.F.R. § 1306.04. A pharmacist who filled for a Houston-area pill mill received 42 months in 2026. The defense rests on the verification performed and the absence of knowledge of the prescriber’s conduct.
Pharmacy Owners, Executives, and Billing Companies
Owners of retail, compounding, specialty, mail-order, and long-term care pharmacies are primary targets, along with the executives, compliance officers, and billing companies above and around them. Prosecutors pursue those who allegedly directed the billing model, designed commission structures that paid for prescriptions, selected ingredients by reimbursement value, or dispensed controlled substances unlawfully. Loss figures reaching the hundreds of millions drive both the guidelines calculation and the forfeiture demand. The defense contests personal knowledge, direction, and intent, documents the compliance program in operation rather than on paper, and tests the loss figure itself.
Sales Representatives and Marketers
Commission compensation tied to prescription volume is the government’s central kickback theory under both the AKS and EKRA, and civil exposure is independent of any indictment: in March 2026, DOJ obtained a $31 million judgment against a pharmacy salesman for referral payments. The defense analyzes the compensation structure, documents the services rendered, and contests the inference that a payment formula establishes corrupt intent.
Prescribing Physicians and Mid-Level Providers
Prescribers are charged when the government alleges they signed compound prescriptions in exchange for payment, prescribed without a genuine treatment relationship, or authorized refills without evaluation. In the compounding cases, prescriptions were often signed for patients never examined, and sometimes never informed. The defense establishes the clinical basis for the prescription and the separation between the prescriber and the pharmacy’s marketing operation.
Telehealth Pharmacy Platforms and 503B Outsourcing Facilities
Platforms that market compounded products directly to consumers, and the outsourcing facilities that supply them, face FDA letters, state board action, brand manufacturer litigation, and criminal referral. FDA’s 2026 letters focus on claims implying equivalence to approved products and branding that obscures the compounder. The firm defends platform executives and facility operators on promotional claims, ingredient sourcing, prescriber oversight, and the line between patient-specific compounding and unapproved manufacturing.
These investigations follow a recognizable sequence. Knowing it tells a pharmacy what the government already has.
Claims Analytics and Purchase Reconciliation
HHS-OIG, DCIS, CMS, and the FBI screen pharmacy billing for outliers: compound volume out of step with peers, reimbursement per prescription far above benchmarks, and repeated use of high-cost ingredients. The most damaging analysis is the simplest. Investigators compare wholesaler purchase records to billed prescriptions, and a pharmacy that billed more than it could have bought has a problem that is hard to explain.
Formulation and Ingredient Analysis
Investigators reconstruct what was in each product and why, looking for ingredients with no therapeutic rationale, formulations that duplicate commercially available drugs, and ingredient changes that track changes in reimbursement. Test claims submitted to determine which combinations paid best are among the government’s strongest exhibits.
Marketing and Compensation Tracing
Investigators trace payments among the pharmacy, prescribers, sales representatives, and marketing companies, and compare them to prescription volume. Percentage-based and per-prescription compensation is treated as evidence of inducement. Contracts, invoices, commission statements, and bank records are used to show whether payment tracked services rendered or referrals generated.
TRICARE and DCIS Investigation
TRICARE matters are worked by the Defense Criminal Investigative Service with DOJ, the FBI, IRS-CI, and the Department of Labor OIG. DCIS screens TRICARE pharmacy claims for compound billing anomalies and traces the chain from the marketer who recruited the beneficiary, through the prescriber who signed, to the pharmacy that billed.
FDA Inspection and Criminal Referral
The FDA inspects compounding pharmacies and outsourcing facilities for copies of commercially available products, bulk substances not on the approved list, current Good Manufacturing Practice failures, and manufacturing without registration. Findings issue as a Form 483 and then a warning letter. Where FDA documents prior notice and continued conduct, the referral that follows is a felony referral.
Qui Tam Complaints and Search Warrants
Many pharmacy investigations begin with a sealed qui tam complaint under the False Claims Act filed by a former pharmacist, technician, sales representative, or competitor, and proceed under seal for a year or more. When the investigation surfaces, agents execute warrants for dispensing records, formulation files, and financial records, and serve cloud warrants under 18 U.S.C. § 2703 for email, text messages, and pharmacy management systems.
These prosecutions stack counts across fraud, kickback, controlled substances, and FDCA statutes, with forfeiture allegations attached.
Healthcare Fraud (18 U.S.C. § 1347)
Section 1347 covers billing for prescriptions never dispensed, compound formulations designed to inflate reimbursement, false prior authorizations, short-fills billed as full quantities, and brand-for-generic substitution. The maximum is 10 years per count, rising to 20 years where serious bodily injury results.
Conspiracy (18 U.S.C. § 1349)
Section 1349 carries the same maximum as the underlying offense and requires no overt act. It joins owners, pharmacists, sales representatives, prescribers, and billing staff in one indictment, and reaches participants who never touched a claim.
Anti-Kickback Statute (42 U.S.C. § 1320a-7b)
The Anti-Kickback Statute is charged in nearly every pharmacy case involving referral payments, including payments to prescribers, marketers, and sales representatives, and routine copay waivers used to induce acceptance of medications. Violations carry up to 10 years each, and a tainted claim is also a false claim for civil purposes.
EKRA (18 U.S.C. § 220)
EKRA reaches referrals to pharmacies regardless of payor, including TRICARE and commercial plans, and carries up to 10 years and a $200,000 fine per violation. Its employee compensation exception is narrower than the corresponding AKS safe harbor, so commission structures built for AKS compliance can still create EKRA exposure.
Wire Fraud (18 U.S.C. § 1343)
Wire fraud captures electronic claim submissions, electronic prescriptions, and interstate communications advancing the scheme, at up to 20 years per count. It also reaches schemes against commercial plans and state employee benefit programs.
Unlawful Dispensing of Controlled Substances (21 U.S.C. § 841)
Section 841 applies when a pharmacist knowingly fills prescriptions lacking a legitimate medical purpose. Schedule II substances carry up to 20 years per count. The same conduct supports parallel civil Controlled Substances Act liability, which is how the chain pharmacy settlements were built.
Food, Drug, and Cosmetic Act Violations (21 U.S.C. §§ 331, 333)
Distributing adulterated or misbranded drugs, compounding outside the conditions of 21 U.S.C. § 353a or § 353b, and marketing unapproved new drugs violate 21 U.S.C. § 331. A violation is a strict liability misdemeanor under § 333(a)(1) and becomes a three-year felony under § 333(a)(2) when committed with intent to defraud or mislead. Prior FDA notice is what the government uses to establish that intent.
Money Laundering and Forfeiture (18 U.S.C. §§ 1956, 1957, 982)
Money laundering counts carry up to 20 years and routinely accompany large pharmacy prosecutions. Forfeiture reaches business accounts, real property, and vehicles, often before trial, and reached $27 million alongside $33 million in restitution in one 2026 compounding sentencing.
False Claims Act, Exclusion, and Licensure
The False Claims Act imposes treble damages and per-claim penalties, and pharmacy claim counts run into the thousands. A conviction or program-related settlement triggers exclusion, which ends a pharmacy’s ability to bill federal programs. DEA revokes the registration, and state boards proceed separately, often on the indictment rather than the verdict.
What Is Driving Federal Pharmacy and Compounding Enforcement in 2026?
Three developments define the year. DOJ created the Health and Safety Unit on November 30, 2025, staffing it with 23 prosecutors to bring criminal Food, Drug, and Cosmetic Act cases, and then created the National Fraud Enforcement Division on April 7, 2026, moving the Healthcare Fraud Unit under it. Fraud and FDCA prosecutions now sit in the same structure.
Civil enforcement reached a record. False Claims Act recoveries exceeded $6.8 billion in fiscal year 2025, with healthcare accounting for more than $5.7 billion and a record 1,297 qui tam filings. Pharmacy matters run throughout that total.
FDA became the most active regulator in the compounding space, issuing successive waves of warning letters over compounded GLP-1 marketing and referring a major telehealth company to DOJ in February 2026. A marketing decision, a formulation decision, and a billing decision now each carry criminal risk from a different agency.
Why Is TRICARE Still a Focus in Compounding Pharmacy Prosecutions?
TRICARE compound drug spending rose from roughly $24 million in 2010 to more than $500 million in 2014. Compounds were under one percent of prescriptions but approximately 20 percent of TRICARE pharmacy costs. That distortion triggered investigations by the Defense Criminal Investigative Service, DOJ, the FBI, and IRS-CI that are still producing trials and sentences a decade later.
In March 2025, two executives of a Louisiana compounding pharmacy were convicted after a six-week trial of defrauding TRICARE and New Jersey benefit programs of approximately $100 million, and fifty people have been convicted or pleaded guilty in that conspiracy. In April 2026, a mail-order pharmacy president received 24 months with $33 million in restitution and $27 million in forfeiture.
How Does the Government Prove a Pharmacy Billed for Drugs It Never Dispensed?
The proof is arithmetic rather than testimony. Investigators obtain wholesaler purchase records and compare quantities acquired against quantities billed to Medicare Part D, Medicaid, TRICARE, and commercial plans. A pharmacy that billed more units than it purchased cannot have dispensed them.
That method drove the January 2026 resolution in which four New Jersey pharmacies paid $4.325 million over claims for drugs never dispensed, where inventory records showed insufficient purchases to fill the billed prescriptions.
The defense works within the same data. Inventory transfers between locations, returns, partial fills, compounded quantities yielded from bulk substances, short-dating, and 340B or contract pharmacy arrangements all affect the comparison, and a purchase-to-billing gap has more than one possible explanation.
What Is the Exposure for Pharmacies Compounding Semaglutide and Other GLP-1 Products?
Once FDA declared the semaglutide and tirzepatide shortages resolved, the statutory basis for compounding copies of those drugs under 21 U.S.C. § 353a and § 353b narrowed sharply. Compounding a product that is essentially a copy of an approved drug outside a documented patient-specific need is the central exposure.
FDA enforcement has been continuous: more than 40 letters to telehealth-based compounding pharmacies in late 2025, 30 in March 2026, an April 2026 round on research-use-only labeling and unapproved agonists, and 25 in June 2026. The agency has said retatrutide and cagrilintide may not be compounded and issued an import alert covering GLP-1 active ingredients.
The criminal risk follows the paper. A violation of 21 U.S.C. § 331 is a misdemeanor with no intent requirement and becomes a three-year felony under § 333(a)(2) when committed with intent to defraud or mislead. A prior warning letter followed by continued conduct is how the government builds that element.
How Does EKRA Apply to Pharmacy Marketing and Sales Compensation?
EKRA prohibits paying or receiving remuneration to induce referrals to a pharmacy, laboratory, or recovery home, and it applies regardless of payor. That reach matters for pharmacies whose volume is commercial or TRICARE rather than Medicare, because the Anti-Kickback Statute alone would not cover it.
The employee compensation exception is narrower than the corresponding AKS safe harbor. Under EKRA, compensation to an employee or contractor may not vary by the number of individuals referred, the number of tests or items furnished, or the amount billed. A commission structure lawful under the AKS employment safe harbor can still violate EKRA, and courts have divided on how the exception applies to sales personnel.
Penalties run to 10 years and a $200,000 fine per violation. The defense work is structural: fixed compensation set in advance, documented duties unrelated to referral volume, fair market value support, and a written agreement that matches what people actually did.
Can a Pharmacist Be Charged for Filling a Prescription Written by a Licensed Physician?
Yes. A pharmacist has an independent corresponding responsibility under 21 C.F.R. § 1306.04 to confirm that a prescription was issued for a legitimate medical purpose. Filling despite red flags supports liability under 21 U.S.C. § 841 regardless of the prescriber’s license. The pharmacist who filled for a Houston-area pill mill received 42 months in 2026.
The flags prosecutors cite are consistent: concentrated volume from a single prescriber, cash payment, patients traveling long distances, early refills, uniform high-strength quantities, and the opioid, benzodiazepine, and muscle relaxant combination, each visible in the pharmacy’s own dispensing data.
In compounding cases the allegation is parallel: that the pharmacist prepared formulations selected for reimbursement value, or filled prescriptions from prescribers with no treatment relationship to the patient. The defense in both settings is the verification performed and documented at the time.
What Compounding Pharmacy Experience Does the Firm Bring to These Cases?
Scott Armstrong served as lead counsel at DOJ’s Fraud Section in a $120 million compounding pharmacy fraud case involving pharmacy executives, pharmacists, prescribing physicians, and marketers. It presented the issues that recur in every compounding prosecution: kickbacks between the pharmacy and prescribers, formulations manipulated to maximize reimbursement, fraudulent billing, and tracing of proceeds through multiple entities. He built it from investigation through charging, analyzing the formulation evidence, developing the financial tracing, and managing the cooperating witness strategy. He also directed DOJ’s ARPO Strike Force.
Drew Bradylyons supervised the Healthcare Fraud Unit’s Florida Strike Force and served as Chief of EDVA’s Financial Crimes and Public Corruption Unit, where he oversaw parallel criminal, civil, and administrative proceedings involving more than $1 billion in claims. The firm’s attorneys have tried 17 federal healthcare fraud jury trials at DOJ.
What Happens When the FDA Inspects a Compounding Pharmacy or Outsourcing Facility?
An inspection typically ends with a Form 483 listing observations. The written response is the first substantive record the facility creates, and FDA weighs it and any corrective action before deciding what comes next. Common findings include compounding copies of commercially available drugs, bulk substances not on the applicable list, sterility and current Good Manufacturing Practice failures, and operating at a scale resembling manufacturing without registration.
A warning letter follows where FDA concludes the violations are significant. Escalation beyond that can include seizure, injunction, or referral to DOJ’s Health and Safety Unit, which was created in November 2025 to prosecute criminal FDCA cases.
The element that changes the exposure is notice. A first violation can be charged as a strict liability misdemeanor, but a violation committed with intent to defraud or mislead is a felony under 21 U.S.C. § 333(a)(2), and prior FDA correspondence is the government’s standard proof of that intent. Inspection responses are therefore written for two audiences.
What Sentences and Financial Penalties Do Pharmacy Fraud Cases Produce?
Criminal sentences track loss and role. Principals in the largest compounding schemes have received 18 years with restitution in the hundreds of millions. In April 2026, a mail-order pharmacy president received 24 months in a $33 million scheme, with $33 million in restitution and $27 million in forfeiture, and a pharmacist who filled for a pill mill received 42 months. Maximums are 10 years per healthcare fraud count, 20 per wire fraud count, 10 per kickback violation, and 20 for Schedule II dispensing counts.
Civil exposure can exceed the criminal exposure and does not require an indictment. A jury returned a $948.8 million judgment against the nation’s largest long-term care pharmacy and its parent for dispensing without valid prescriptions. Walgreens agreed to pay up to $350 million over invalid controlled substance prescriptions, and Walmart resolved the government’s dispensing case for $50 million in August 2026.
Program consequences are often decisive. Exclusion ends a pharmacy’s ability to bill federal programs, DEA revocation ends controlled substance dispensing, and state board action follows independently.
What Does a DEA Immediate Suspension Order Mean for a Pharmacy?
An Immediate Suspension Order under 21 U.S.C. § 824(d) suspends the registration the moment it is served, on a finding of imminent danger to public health or safety. All controlled substance dispensing stops that day, before any hearing, and DEA may place the pharmacy’s controlled substances under seal. For most retail pharmacies, that halts a substantial share of the business immediately.
An Order to Show Cause is different. The registration remains active, the pharmacy has 30 days to answer and request a hearing, and allegations left unanswered are deemed admitted. A registrant served with an Order to Show Cause may also submit a corrective action plan under § 824(c); a registrant served with an Immediate Suspension Order may not.
DEA reported a record 928 actions against registrants in the year ending with the June 2026 takedown: 205 Orders to Show Cause, 53 Immediate Suspension Orders, and 642 surrenders for cause. A surrender signed during a field visit ends the registration with no hearing and no review of the agency’s evidence.
How Do Qui Tam Whistleblower Complaints Begin Pharmacy Investigations?
A former pharmacist, technician, billing employee, sales representative, or competitor files a complaint under seal under the False Claims Act. The government investigates while the case remains sealed, and the pharmacy may not learn of it for a year or more. Civil investigative demands, subpoenas, and interviews of former employees often surface before the complaint does.
Qui tam filings hit a record 1,297 in fiscal year 2025, generating $5.3 billion in recoveries. Pharmacy allegations typically involve billing for drugs never dispensed, kickbacks to prescribers or marketers, compounding built around reimbursement, and routine copay waivers. The criminal and civil tracks frequently run together.